ArticleACS synthetic biology2026
Systematic Evaluation of Vector Sequence Elements in Isogenic CHO Cells for Improved Antibody Production.
Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) constitute a leading class of biotherapeutics, and meeting global demand requires manufacturing platforms that deliver rapid and reliable expression. Nevertheless, efficient and predictable production remains challenging because multiple vector elements can substantially influence productivity and product quality. In this study, we examined how sequence design features influence expression in a targeted-integration CHO system using six antibodies (A-F). We evaluated codon usage in the constant light (CL) and constant heavy (CH) regions with and without LALA/YTE Fc mutations, the type of signal peptide, codon optimization of the variable regions, and substitution of the kappa light chain with lambda. We found that changing codons of CL and CH to suboptimal codons reduced expression for all six antibodies, independent of LALA/YTE status. Replacing chain-specific signal peptides with a single identical peptide produced antibody-specific outcomes: productivity decreased for four antibodies (A, C, D, and E), increased for antibody B by ∼1.5-fold, and remained unchanged for antibody F. In addition, codon optimization of the variable regions generally enhanced productivity in an antibody-dependent manner, with improvements ranging from ∼2-fold to ∼18-fold. Finally, substituting kappa with lambda decreased productivity for three antibodies, suggesting a CHO cell preference for the kappa isotype. Collectively, these findings delineate practical sequence-engineering principles for CHO expression, prioritize codon usage in constant and variable domains, maintain chain-appropriate signal peptides, and account for kappa/lambda dependencies, thereby improving construct selection and accelerating development of high-yielding mAb producers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.